Patent ID: 9333217
Filing Date: 2016-05-10
CPC Classification: A61K,A61P,C07D,C12Q,G01N

Claim Text:
1. A method for treating cancer in a subject, comprising (i) contacting a biological sample obtained from the subject with at least one antibody that binds specifically to a mutant Enhancer of Zeste Homolog 2 (EZH2) comprising a mutation at position Y641 in the EZH2 of SEQ ID NO: 1, wherein the mutation increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27), wherein the mutation at position Y641 in the EZH2 of SEQ ID NO: 1 is selected from the group consisting of Y641F, Y641H, Y641N and Y641S, and wherein the at least one antibody and the mutant form a complex; (ii) detecting the presence of the mutation at position Y641 in the EZH2 of SEQ ID NO: 1 by detecting the complex formed in step (i); and (iii) administering a therapeutically effective amount of an inhibitor of EZH2 to the subject if the mutation at position Y641 in the EZH2 of SEQ ID NO: 1 is detected in the biological sample obtained from the subject, wherein the EZH2 inhibitor inhibits the conversion of H3-K27 to trimethylated H3-K27.